ArticleDiscover oncology2025
Establishment of M2 macrophage-related prognostic signature in pancreatic ductal adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- TGFβ Blockade by Inhibition of Enolase-1-Mediated Plasmin Targets Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by significant heterogeneity and a poor prognosis. M2 macrophages (M2) play a crucial role in the microenvironment of PDAC, yet their exact functional significance remains poorly understood. This study sought to explore the potential communication and clinical implications of M2 in PDAC. The differentiation pathway of M2 and their interaction with malignant PDAC cells were analyzed using single-cell RNA sequencing (scRNA-seq). Additionally, a prognostic signature related to M2 marker genes was constructed and analyzed using bulk RNA sequencing. Three distinct differentiation states of M2 were characterized, each exhibiting unique transcription factor expression profiles and signaling pathway activations. Potential intercellular communication between M2, PDAC malignant cells, and fibroblasts was initially observed at the level of computer analysis. The prognostic model was identified through the LASSO algorithm. Patients stratified by risk level displayed significant variations in prognostic indicators such as signaling pathway activity, gene mutation frequency, immune cell infiltration, and drug sensitivity. These findings are of course preliminary, and future in vitro/in vivo experiments will be needed to knock out these signature genes or ligand-receptor pairs of genes in macrophages to validate their role in macrophage development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.